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Abstract
Objectives: Initial results in robot-assisted middle pancreatectomy (MP) have been encouraging.
However, data comparing outcomes of robot-assisted MP with those of open MP are limited. The aim of
this study was to compare outcomes in patients undergoing open and robot-assisted MP, respectively.
Methods: Outcomes in an initial experience with seven consecutive patients undergoing robot-assisted
MP were compared with those in 36 patients undergoing open MP.
Results: The robot-assisted MP group included five women and two men with a median age of 55 years
(range: 30–62 years). Median tumour size, operative time and blood loss were 3.0 cm (range: 0.5–5.0 cm),
210 min (range: 150–330 min) and 200 ml (range: 50–400 ml), respectively. Pancreaticogastrostomy was
performed in all patients. No transfusion was given intraoperatively. Pathological examination revealed
five serous cystic neoplasms, one mixed-type intraductal papillary mucinous neoplasm and one lipoma.
Five patients experienced postoperative pancreatic fistula and one experienced post-pancreatectomy
haemorrhage. No operative mortality was noted. Compared with the open MP group, the robot-assisted
MP group demonstrated a shorter median length of postoperative gastrointestinal tract recovery [2 days
(range: 2–3 days) versus 4 days (range: 2–11 days); P = 0.001].
Conclusions: Robot-assisted MP can be performed safely with satisfactory efficacy; patients experi-
enced faster gastrointestinal tract recovery compared with patients undergoing open surgery.
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Introduction
In recent years, there has been growing interest in parenchyma-
sparing pancreatic surgeries for benign, borderline or low-grade
malignant lesions of the pancreas, especially in young patients
with long life expectancies; these surgeries aim to preserve exo-
crine and endocrine pancreatic function, and facilitate a better
quality of life after surgery.1–5 Middle pancreatectomy (MP), for
example, serves as an alternative to extended right or left pancre-
atic resection for the treatment of benign, borderline or low-grade
malignant lesions of the neck or the proximal body of the
pancreas.2,4,5 Since it was first reported by Guillemin and Bessot in
1957,6 MP has been studied intensively and is now generally
accepted as a safe and effective procedure, especially in terms of
pancreatic function preservation.2,4,5
However, the application of minimally invasive approaches to
MP has been disappointing. The first laparoscopic MP was
described by Baca and Bokan in 2003,7 but few centres have
adopted this minimally invasive approach. This is mainly because
of the technical difficulty associated with this procedure during
the reconstruction phase, although various reports have con-
firmed the safety and feasibility of the technique.7–12
The robot-assisted surgical system is an emerging technology
which has been designed to overcome the intrinsic limitations of
traditional laparoscopic surgery by offering three-dimensional
surgical views, the facility for precise and flexible wrist-like move-
ments, lack of tremor, reliable fourth-arm movement and better
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ergonomics for surgeons.13 In fact, the robotic approach has been
shown to be safe and feasible for complex and difficult pancreatic
resections, including those that require pancreaticoenteric or vas-
cular reconstruction.13–17
Studies comparing the outcomes of robot-assisted and open
MP are rare. Therefore, at a time when the number of procedures
performed using the robotic approach is increasing, it is of great
significance to evaluate whether such an approach offers any
advantages over open surgery. The aim of the current study was to
compare outcomes in patients undergoing open and robot-
assisted MP, respectively.
Materials and methods
The present authors retrospectively reviewed the medical charts of
patients who were initially scheduled to undergo robot-assisted
MP using the da Vinci® Surgical System (Intuitive Surgical, Inc.,
Sunnyvale, CA, USA) between March 2010 and July 2011. Data
collected and analysed included gender, age, symptoms, patho-
logic diagnosis, tumour size, operative time, estimated intraop-
erative blood loss, transfusion rate, conversion rate, length of
postoperative gastrointestinal tract recovery, postoperative
hospital length of stay (LoS), postoperative pancreatic fistula,
morbidity, mortality, pathology and follow-up. Conversion in the
robot-assisted group was defined by the inability to terminate the
operation using a robotic approach.
To provide a comparative analysis, the authors reviewed the
medical charts of patients who underwent open MP between April
2003 and December 2009. A total of 40 patients were identified.
Four patients were found to have had invasive malignant tumours
on final pathologic examination and were excluded from the
present study. A comparison of perioperative clinicopathologic
characteristics between the two groups was conducted. The design
of this study was approved by the authors’ institutional review
board.
Pancreatic fistula was defined according to the guidelines of
the International Study Group on Pancreatic Fistula.18 Post-
pancreatectomy haemorrhage was defined according to the
guidelines of the International Study Group of Pancreatic Sur-
gery.19 Operative time was calculated as the time between skin
incision and skin closure in the open surgery group, and as the
time between skin incision and skin closure of the last port in
the robot-assisted surgery group. Complications were defined as
those occurring within 60 days of surgery. Postoperative gas-
trointestinal tract recovery was defined as the time to first flatus
after surgery. Mortality was defined as death within the 60 days
post-surgery in or out of hospital. Outpatient records combined
with telephone interviews were used for follow-up. The
follow-up period was defined as the interval between the day of
operation and the day of the last follow-up. Follow-up was
updated in May 2012. Exocrine deficiency was defined as either
new-onset diabetes or deterioration in the metabolic control of
previously diagnosed diabetes. Exocrine deficiency was defined
as steatorrhea and weight loss requiring pancreatic enzymes
supplementation.
The indication for MP during the study period was a lesion
located in the neck or proximal body of the pancreas with no
evidence of high-grade malignancy that could not be treated with
enucleation. To select candidates for this procedure, computed
tomography and ultrasonography were routinely performed.
Additionally, magnetic resonance imaging, endoscopic ultra-
sonography and endoscopic retrograde cholangiopancreatogra-
phy were used at the discretion of the surgeon. Intraoperative
frozen-section examination was conducted as part of the surgical
protocol to confirm negative margins and frozen pathology was
performed in the event of suspected adenocarcinoma. If negative
margins were not achieved, subsequent resections and frozen sec-
tions were undertaken to achieve negative margins when possible.
Negative resection margins were confirmed pathologically in all
patients who underwent MP (open and robotic) in the present
study.
In the open surgery group, the proximal pancreatic resection
was performed with a stapler, electrocautery or knife according to
the surgeon’s preference. Then the proximal pancreatic stump was
closed with continuous or interrupted stitches without special
identification and ligation of the main pancreatic duct. The distal
pancreatic stump was reconstructed by pancreaticojejunostomy
(duct-to-mucosa or invagination) or pancreaticogastrostomy
according to the surgeon’s preference. Internal stent drainage was
carried out as routine practice.
In the robot-assisted surgery group, all patients were operated
using a totally robotic approach. The dissection phase was gener-
ally similar to that described in the open surgery group. The
remnant pancreas was managed by pancreaticogastrostomy with
internal stent drainage without a transgastric approach. All
robotic and open procedures were performed by the same sur-
geons (CP and BS).
The operative technique for robot-assisted MP was first
described by Giulianotti et al.14 Modifications were later reported
by Addeo et al.16 and Kang et al.20 The technique used for patients
in the current study was as follows. Patient positioning and setting
of trocars were generally the same as those described by Giulian-
otti et al.14 Four trocars were placed for access by the robotic arms,
and an additional 12-mm trocar was placed for the assistant’s
access (Fig. 1). The da Vinci® surgical arm cart was then docked.
The lesser sac was entered by opening the gastrocolic ligament; the
posterior gastric wall was lifted and retracted cranially using the
fourth robotic arm, exposing the pancreas. The anterior surface of
the portal vein was dissected at the superior edge of the pancreatic
body (Fig. 2a). The superior mesenteric vein (SMV) was exposed
at the inferior edge of the pancreatic neck. A retropancreatic
tunnel was then created under the pancreatic neck by gentle dis-
section with tangential movements in relation to the vascular axis
(Fig. 2b). Upon completion of the tunnel, the pancreatic neck was
transected using an endoscopic stapler (Fig. 2c) or an ultrasonic
scalpel. Interrupted stitches of polypropylene 4–0 were applied to
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the proximal stump selectively with the aim of achieving satisfac-
tory homeostasis and reducing the risk for postoperative pancre-
atic fistula. The distal pancreas was then dissected progressively
between the pancreas and splenic vessels to ensure a free resection
margin. Small branches of the splenic vein and artery, to and from
the pancreas, were selectively clipped or ligated and then
transected (Fig. 2d). The transection of the pancreatic body was
performed on the left side of the lesion using the robotic ultraci-
sion device (Fig. 2e). Afterwards, the distal stump was dissected
about 2 cm to facilitate ensuing pancreaticogastrostomy (Fig. 2f).
A short stent was inserted into the pancreatic duct without
fixation (Fig. 3a). The fourth arm was used to retract the posterior
gastric wall in a stable position. Two-layer pancreaticogastrostomy
was then carried out. Firstly, a posterior outer layer suture was
performed and the anterior wall of the distal pancreatic remnant
was anastomosed to the posterior wall of the gastric body using
interrupted stitches of 4–0 non-absorbable sutures from the pan-
creatic parenchyma to the gastric seromuscular layer (Fig. 3b).
Once the posterior outer layer suture was finished, a 3–4-cm inci-
sion was made at the posterior wall of the gastric body using a
monopolar hook. Then, suture of the posterior inner layer was
performed using interrupted stitches of 4–0 non-absorbable
sutures from the stump of the distal pancreatic remnant to the full
layer of the gastric body (Fig. 3c). Subsequently, the distal stump
along with a stent was put into the stomach (Fig. 3d). In the same
way as the posterior layer suture, an anterior inner layer suture
(Fig. 3e) followed by an anterior outer layer suture was performed
(Fig. 3f). Two double-lumen drainage tubes were placed near the
ends of the proximal pancreatic stump and at the site of anasto-
mosis, respectively.
Variables are expressed as the median and range, and as
numbers. Statistical analysis was performed using spss Version
19.0 for Windows (SPSS, Inc., Chicago, IL, USA). A two-sided
P-value of < 0.05 was considered to indicate statistical signifi-
cance. Comparisons between the two groups were determined
using Fisher’s exact test for discrete variables and Mann–Whitney
U-test for continuous variables.
Results
Data comparing patients undergoing robot-assisted and open MP,
respectively, are shown in Table 1. All robotic procedures were
successfully completed without conversion. Five patients in the
robot-assisted surgery group developed postoperative pancreatic
fistulae, all of which were Grade B. Fifteen patients in the open
surgery group developed postoperative pancreatic fistulae, of
which nine were Grade A and six were Grade B. One patient in the
robotic surgery group suffered a post-pancreatectomy haemor-
rhage (Grade B). No patient required reoperation in either group.
Follow-up was complete in all patients in the robot-assisted
surgery group and in 30 patients (83.3%) in the open surgery
group. Of the six patients lost to follow-up, three died of other
disease during follow-up. The median follow-up was 23 months
(range: 10–25 months) in the robotic surgery group and
62 months (range: 31–108 months) in the open surgery group. All
patients showed no evidence of tumour recurrence. In the robotic
surgery group, no patient showed signs of exocrine or endocrine
deficiency. In the open surgery group, three patients developed
new-onset diabetes, but no diabetic deterioration was observed in
the five patients with preoperative diabetes and no patient showed
signs of exocrine deficiency.
Discussion
Recently, parenchyma-sparing pancreatic surgeries for benign,
borderline or low-grade malignant lesions of the pancreas have
gained increasing attention.1,3 Several factors may have contrib-
uted to this development, including evolving methods and greater
confidence in the prevention and treatment of pancreatic fistula,21
better knowledge of the natural history of certain pancreatic
neoplasms,22–24 and growth in the numbers of asymptomatic non-
invasive lesions diagnosed as a result of the widespread availability
of high-resolution imaging techniques.25 Middle pancreatectomy,
which is indicated for the treatment of benign, borderline and
low-grade malignant lesions of the neck or proximal body of the
pancreas in place of extended right or left pancreatic resection, is
currently accepted as a rational parenchyma-sparing procedure
not only in terms of safety and effectiveness, but also in terms of
the preservation of pancreatic function.2,4,5
Meanwhile, minimally invasive surgical techniques have been
increasingly applied in pancreatic surgery in an effort to decrease
the morbidity associated with open surgery.8,10,26 This is particu-
larly true for distal pancreatic resections, which account for most
resections currently performed using laparoscopy because they
can be carried out with relative ease and do not require recon-
struction.26 However, only approximately 20 laparoscopic MP
Figure 1 Ports for middle pancreatectomy. C, 12-mm trocar for
camera; R1, 8-mm trocar for robotic arm 1; R2, 8-mm trocar for
robotic arm 2; R3, 8-mm trocar for robotic arm 3; A, 12-mm trocar
for assistant instruments
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procedures have been reported so far,7–12 which indicates that this
is a demanding procedure, mainly because of the intrinsic limita-
tions of laparoscopy.
In order to compensate for the disadvantages of conventional
laparoscopy, robot-assisted surgery has been introduced and
is slowly gaining acceptance, even in complex and difficult
pancreatic resections that require pancreaticoenteric or vascular
reconstruction,13–17 thereby making minimally invasive techniques
in demanding pancreatic procedures such as MP now possible
(Table 2). However, information on the advantages of using a
robotic approach rather than open surgery in MP is rare. There-
fore, a comparison of the outcomes of robot-assisted and open
MP was performed.
Since the da Vinci® robot-assisted surgical system became
locally available in March 2010, a selective robotic approach in
pancreatic surgery has been adopted, especially for parenchyma-
sparing resections.27 Over the past 2 years to date, seven consecu-
tive patients have been scheduled to undergo robot-assisted MP,
all of whom did so successfully without conversion. All seven of
the patients had benign, borderline and low-grade malignant
tumours. Four patients with asymptomatic serous cystic neo-
plasms which met current recommendations for resection28
underwent robot-assisted MP in the present study. Of these, one
had a tumour of 5 cm in diameter and one had a tumour with a
progressive increase in diameter to 4 cm. In the remaining two
patients, the diagnosis of mucinous cystic neoplasm could not be
safely excluded preoperatively.
Minimal surgical trauma should represent the initial goal of
minimally invasive pancreatic surgery. However, in the current
series, the use of robotic surgery did not incur a statistically
significant reduction in intraoperative estimated blood loss. By
contrast, unlike previous reports of increased operative time in
robot-assisted surgery,20 the current experience showed that the
operative time required to complete robot-assisted MP was com-
parable with that required for open MP. These results are encour-
aging; it would seem that robot-assisted surgery may become
associated with operative time that is at least comparable and
potentially shorter than that in open surgery as surgeons accumu-
late more experience.
As Giulianotti et al.14 reported in a description of the world’s
first robot-assisted MP in 2010, two phases of this surgical proce-
dure are greatly facilitated by the robotic system; these include the
dissection of the pancreatic body from the splenic vessels and the
pancreaticoenteric reconstruction. The three-dimensional vision
and the flexible wrist-like movements afforded by the robotic
system guarantee the easier recognition and dissection of the
Figure 2 Dissection phase. (a) The anterior surface of the portal vein is exposed at the superior edge of the pancreatic body. (b) A
retropancreatic tunnel is created. (c) The pancreatic neck is transected at the right side of the lesion; the common hepatic artery is carefully
protected. (d) The pancreatic body is dissected from the splenic vessels. The white arrow shows the management of a small branch of
splenic vein. (e) The pancreatic body is transected on the left side of the lesion. (f) The distal stump of the pancreas is prepared for
pancreaticogastrostomy. The white arrow shows the management of a small branch of splenic artery. CHA, common hepatic artery; Pan,
pancreas; PV, portal vein; SMV, superior mesenteric vein; SpA, splenic artery; SpV, splenic vein
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Figure 3 Reconstruction phase. (a) The pancreatic duct is stented. (b) The posterior outer layer is sutured. (c) The posterior inner layer is
sutured. (d) The distal stump of the pancreas along with a stent is put into the stomach. (e) The anterior inner layer is sutured. (f) The anterior
outer layer is sutured. Pan, pancreas; SpA, splenic artery; SpV, splenic vein; stomach, posterior wall of the stomach
Table 1 Comparison between patients undergoing robot-assisted and open middle pancreatectomy
Robot-assisted
surgery group
(n = 7)
Open surgery
group
(n = 36)
P-value
Age, years, median (range) 55.0 (30–62) 51.5 (23–76) 0.856
Female gender, n 5 27 1.000
Symptoms, n 2 16 0.680
Tumour size, cm, median (range) 3.0 (0.5–5.0) 2.1 (0.4–6.2) 0.551
Operation time, min, median (range) 210 (150–300) 226 (100–332) 0.489
Estimated blood loss, ml, median (range) 200 (50–400) 200 (50–1500) 0.432
Blood transfusion, n 0 5 0.572
Remnant reconstruction, PJ/PG, n 0/7 22/14 0.004
Diagnosis, n 0.134a
Serous cystic neoplasm 5 16
Intraductal papillary mucinous neoplasm 1 3
Other 1 17
Pancreatic fistula, n 5 15 0.222
Complications, n 6 18 0.112
GI tract recovery, days, median (range) 2 (2–3) 4 (2–11) 0.001
Postoperative LoS, days, median (range) 21 (13–33) 18 (11–107) 0.587
Mortality, n 0 0 1.000
aKruskal–Wallis H test.
PJ, pancreaticojejunostomy; PG, pancreaticogastrostomy; GI, gastrointestinal; LoS, length of stay.
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small tributaries of the splenic vessels directed to and from the
pancreatic body14 (Fig. 2d–f). In addition, the fourth arm of the
robotic system provides a stable platform from which to operate.
During the reconstructive phase, pancreaticogastrostomy has
so far represented the preferred choice in robot-assisted MP,14,16,20
despite the ability to perform robotic pancreaticojejunostomy.15
Pancreaticogastrostomy does not require bowel mobilization and
division and thereby avoids any increase in operative time, the
interruption of intestinal continuity and potential leaks. The
present authors have adopted a two-layer pancreaticogastrostomy
with internal stent drainage (Fig. 3), which resembles the proce-
dure carried out in patients undergoing open MP with pancrea-
ticogastrostomy. External stenting was not performed16 and a
transgastric approach to pancreaticogastrostomy20 was not
adopted for patients in this series because of the additional time
and trauma associated with these methods and the potential risk
for gastric leakage.
The most predominant complication and biggest concern asso-
ciated with cases of MP reported in the literature is the occurrence
of pancreatic fistula, which has been reported to occur at frequen-
cies of 8–50%.2,4,5 The presence of two pancreatic stumps and a
soft pancreatic parenchyma may be primarily responsible for this
finding. Neither the approach (open, laparoscopic or robotic) nor
the type of reconstruction (pancreaticogastrostomy or pancreati-
cojejunostomy) appear to affect the occurrence of pancreatic fis-
tula.2,4,10,12,14,15,20 The incidence of pancreatic fistula in the robotic
surgery group in the current study was comparable with those in
previous reports of robot-assisted surgery, which ranged from
20% to 75%.14,15,20 Although the difference between the two
groups in the present study was not statistically significant, the
rate of pancreatic fistula was higher in the robotic surgery group.
However, the postoperative hospital LoS did not increase, which
may largely reflect the results of the minimal trauma caused by the
robotic procedure. Further, in the present study, median time to
postoperative gastrointestinal tract recovery was significantly
shorter in the robot-assisted surgery group than in the open
surgery group [2 days (range: 2–3 days) versus 4 days (range: 2–11
days); P = 0.001]. Overall, the present authors consider that the
potential advantages of the robotic approach might be neutralized
by the high rate of postoperative pancreatic fistula identified in the
current study. As a result of differences among health care systems,
the postoperative hospital LoS was much longer in the present
study than at other centres.14,16,20 Despite the excellent technical
improvements in robotic surgical systems, it is presumed that
performing the operation as precisely as in open surgery will
require the surgeon to progress along a learning curve. Thus, the
present authors believe that the accumulation of experience
beyond the learning curve phase may decrease the complication
rate.
Many authors have cited the costs associated with the use of
robotic technology.13,15,20 This was not assessed in the present
series because patients were required to pay an additional sum of
money if they chose to be operated using a robotic approach at the
time they gave informed consent to the procedure. Thus it was
certain that the robotic approach would entail an initial increase
in cost. Whether the potential benefits to be derived from robot-
assisted surgery may counterbalance the overall costs of surgery
remains unknown and requires further investigation.
In conclusion, although the present study is subject to obvious
limitations imposed by the small number of patients investigated,
the study’s retrospective design and a degree of selection bias, the
current experience demonstrates that it is safe and feasible to
perform MP in selected patients using a robotic system and that
patients undergoing robot-assisted MP may benefit from a
quicker gastrointestinal tract recovery. Larger series and control-
led trials comparing outcomes of robot-assisted and open MP are
necessary in order to fully elucidate these potential advantages.
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